Industry
Latham & Watkins Issues October Drug Pricing Digest
In its October 2026 Drug Pricing Digest, Latham & Watkins' Drug Pricing and Market Access team compiles recent developments across healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state drug pricing law. The digest serves as a recurring tracker rather than a report on a single event, aggregating regulatory and legal activity relevant to pharmaceutical manufacturers, covered entities, and payers. No specific new rule, ruling, or action is detailed in the summary provided. Readers rely on the digest to monitor the evolving drug pricing landscape across federal and state levels.
Why it mattersManufacturers, covered entities, and state Medicaid agencies use such trackers to stay ahead of overlapping Medicaid Drug Rebate Program, 340B, and state pricing compliance obligations.